Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01113619 · ClinicalTrials.gov registry record · Phase 2
Effectiveness, Safety and Tolerability Study of RP-G28 for Symptoms Associated With Lactose Intolerance
A Phase 2 study of Lactose Intolerance, sponsored by Ritter Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
- 2
- Study locations
NCT01113619: Completed Phase 2 study of Lactose Intolerance, sponsored by Ritter Pharmaceuticals.
NCT01113619 is a Phase 2 study of Lactose Intolerance that has completed, run by Ritter Pharmaceuticals. The registered enrollment target is 61 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (54% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01113619, a Phase 2 study of Lactose Intolerance, has completed, sponsored by Ritter Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a Phase 2 study designed to assess the ability of RP-G28 to improve lactose digestion and tolerance.
Conditions Studied
Interventions
- DRUG RP-G28 or placebo
Study Locations (2)
Hawaii
- Covance, Inc. - Honolulu - Honolulu
Texas
- Covance, Inc. - Dallas - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2011-04 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
What the finished NCT01113619 record still lists
NCT01113619 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 61 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (54% lower).
The record links to 1 condition, with Lactose Intolerance appearing as the primary indexed condition, and to 1 intervention - of which RP-G28 or placebo is the first listed.
NCT01113619 reports a single indexed study location in Hawaii, Texas.
Frequently Asked Questions
What is clinical trial NCT01113619 about?
NCT01113619 is a clinical study titled "Effectiveness, Safety and Tolerability Study of RP-G28 for Symptoms Associated With Lactose Intolerance". This is a Phase 2 study designed to assess the ability of RP-G28 to improve lactose digestion and tolerance.
What is the current status of trial NCT01113619?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2011-04. Estimated completion is 2011-12.
What conditions does trial NCT01113619 study?
This clinical trial studies the following conditions: Lactose Intolerance.
What interventions are being tested in trial NCT01113619?
The interventions under investigation include: RP-G28 or placebo (DRUG).
Who is sponsoring clinical trial NCT01113619?
This trial is sponsored by Ritter Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01113619 being conducted?
This trial has 2 study locations across Hawaii, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01113619's enrollment target sits among peer trials
61 1026th of 2000 higher than 974 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04115306 · 61 participants · Phase 1
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
- NCT05070845 · 61 participants · Phase 2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
- NCT05187832 · 61 participants · Phase 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
- NCT05269316 · 61 participants · Phase 1
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia